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Rx odds ratio p value 95% C.I.
A+B 197 0.51 <0.01 033-0.79
A+B+C 558 0.58 <0.01 0.42-0.81
B 429 0.66 003 0.46-095
B+C 794 0.7 002 052-0.95
A+C 291 0.96 081 0.67-137
A 197 1.16 0.47 0.78-1.72
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Rx with A in combination with 8 significantly improves mortality when com-
pared to Rx with C even after controlling for CHF Significant differences in
the prevalence of CH F in various Rx groups (53% in A and 5% in Band 11 %
in C) and inability to adequately control for the severity of CHF may explain
the observed effect of Rx with A alone. Conclusions: Combination Rx with A
and 8 is preferable to Rx with Calone. It appears that mortality benefit ofACE
Inhibition in patients with CAD is not limited to patients who have CHF
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1787-31 Efficacy and Safety of Early Administration of
Intravenous Enalaprllat in Congestive Heart Failure
Patients with Acute Pulmonary Edema
Djillali Annane, Eric Bellissant, Eric Pussard, Roland Asmar, Florence Lacombe,
Olivier Madonna, Michel Safar, Jean-Fran~ois Giudicelli, Philippe Gajdos.
Reanimation Medicafe, H6pital R. Poincare, Garches, France
The systemic (Swan-Ganz cathet r, brachial sphygmomanometer) and EIl-
gional (20 pulsed doppler, paraaminohippurate and indocyanine green clear-
ances) hemodynamic and blood gases effects of a single intravenous 2-h-
infusion of 1 mg enalaprilat (E) were investigated within the 12 h following
an acute pulmonary edema episode and compared to those of a placebo (P)
in a randomized double-blind study performed in 20 CHF 11I1-IV NYHA) pa-
tients. The effects were investigated before and 2, 4 and 8 h after the onset
of treatment infusion. At peak effect, and as compared to P, E significantly
decreased pulmonary wedge pressure (-37 vs -10%, P = 0.001), diastolic
and mean systemic (-21 vs -4%, P = 0.009, -18 vs -6%, p ~ 0.026) and
pulmonary (-21 vs -8%, p = 0.040, -18 vs -9%, p = 0.046) arterial pres-
sures, brachial and renal resistances (-44 vs -14%, P = 0.017, -22 vs -2%,
P = 0.014) and significantly increased brachial and renal blood flows (+ 77
vs +8%, P = 0.036, + 12 vs 0%, p = 0.043) arterial oxygen tension (+ 2 vs
-8%, P = 0.041) and saturation (+ 1vs -2%, P = 0.045) and finally tended to
improve intra-pulmonary shunt (-18 vs -16%, P = 0.080). Simultaneously,
E did not affect heart rate, cardiac output, systolic systemic and pulmonary
arterial pressures, and carotid and hepato-splanchnic hemodynamics. Time
courses of plasma electrolytes, creatinine and nitrogen clearances were not
significantly different between E and P. We conclude that in this study early
administration of intravenous enalaprilat was effective and well tolerated in
CHF patients with acute pulmonary edema.
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1787-41 The Paradox of Low Risk Among High Risk Patients
in Controlled Trials - Experience In the TRAndolapril
Cardiac Evaluation Trial
Lars K"ber, Christian Torp-Pedersen, TRACE study group. Gentofte University
Hospital, Copenhagen, Denmark
Mortality in epidemiological studies is almost always larger than in appar-
ently similar populations selected for a clinical trial. To study this problem,
patient inclusion was tracked very carefully in the Trandolapril Cardiac eval-
uation (TRACE) trial.
The TRACE Register includes 7001 consecutive enzyme confirmed MIs in
6676 patients screened for entry into the trial. Medical history and compli-
cations of MI were obtained for all patients. Left ventricular systolic function
was determined by echocardiography in a core laboratory as wall motion
index (WMI) within 6 days of the infarction. Patients with WMI S 12 were
eligible for the study (corresponding to an ejection fraction below 35%) un-
less an exclusion criterion was present. Patients excluded were those not
tolerating or requiring an ACE inhibitor, those dying during screening phase
and those unwillinglunable to participate. Survival data were available for all
except 5 patients after 2-3 years.
The table shows number of MI and 1 year mortality in all patients, and
patients subgroubed by left ventricular systolic function. Also shown is pa-
tients with left ventricular dysfunction subgroubed by whether they were
randomised.
Conclusion: Even though the target population of high risk patients with
reduced left ventricular function was successfully identified, the final study
population had a 1 year mortality similar to unselected patients. This was
caused by exclusion of patients at extreme risk.
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1787-51 Systemic Effect of Ramipril on Endothelin, but not on
Eicosanoid Levels in Patients with Coronary Artery
Disease
Bernhard R. Winkelmann, Gerian Granefeld, Karen Nelson, Matti Verho,
Norbert Bender, Roland Kirsten, Wolfgang Schulz, Martin Kaltenbach. Johann
Wolfgang Goethe-University and Cardiovascular Research Hoechst and Cassella AG,
Frankfurt. Germany
Study aim: Neurohumoral effects of ramipril (R) alone or in combination with
isosorbide dinitrate (ISDN) compared to ISDN or placebo.
Study design: Placebo-controlled double-blind parallel group trial.
Methods: 32 patients with coronary artery disease (CAD) received placebo,
R 5 mg, ISDN 20 mg slow release b.Ld. or R + ISDN for one week. A 24 hour
kinetic profile of ramipril and its metabolite, of ace activity (ACE-A) and of re-
lated hormones (renin and aldosterone), of endothelin and of prostaglandins
(pG), thromboxane B2 {TXB2l. PGF2a, 6-keto PGF1 a, the stable metabolite of
prostacyclin (PGI2-M) was studied after the first dose. Measurements were
repeated after 8 days of treatment before and 3 hours after the morning
dose.
Results: Hormone measurements are presented as means of percent dif-
ference of patients treated with R (n = 16) vs. those without ace-inhibitor (n
= 16).
Time (hrs) a 1 2 3 4 6 8 24 Q-B 3-8
Ramipril(mgm a 8 5 4 3 2 1 0.4 1 7
Ramiprilat(mg/l) a 6 11 10 8 7 5 1 2 14
ACE-A(%) -6 -78 -95 -98 -98 -97 -96 -80 -82 -98
Aldosteron (%) 9 -5 -31 -34 -21 -27 -23 -34
Renin (%) -9 -7 7 19 13 17 53 32
Endothelin (%) -17 -13 -25 -19 -16 -15 -4 a
TXB2 (%) 4 10 4 5 5 a 12 -3
PGF2a 1%) 10 17 0 0 8 2 2 -9
PGI2-M(%) 7 a -3 8 -5 9 -1 -7 13
- = not done; significant differences are printed in italics (two-tailed t-test)
A single oral dose of 5 mg R reduced ACE activity (p < 0.001), decreased
aldosterone and increased renin (p < 0.1). R did not influence plasma levels
of the vasoconstricting (TXB2, PGF2al or vasodilating {pGI2-MI eicosanoid
mediators, but decreased endothelin (p < 0.1).
Conclusion: R, in a dose that results in significant systemic inhibition of the
renin angiotensin aldosteron system, does not induce measurable changes
of circulating eicosanoid concentrations, but seems to diminish systemic
release of endothelin.
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Hypotension Induced by Captopril in Patients with
Primary Autonomic Failure Occurs Independently of
Plasma Renin Levels and Sympathetic Nervous
Activity
J.S. Kooner 1, R. Baliga 1, WS. Peart, c.J. Mathias. 1Royal Postgraduate Medical
School, Hammersmith Hospital, London, UK.; St Mary's Hospital Medical School,
London, UK.
We have investigated the haemodynamic and hormonal responses to an-
giotensin converting enzyme inhibition in 12 patients with primary autonomic
failure (AF, 5 pure autonomic failure, 7 multiple system atrophy) and 7 nor-
mal subjects. Measurements of blood pressure (BP). heart rate (HR). stroke
distance (SO) and cardiac index (CI, continuous wave Doppler, forearm blood
flow (FBF, strain gauge plethysmography) and digital skin blood flow (DSBF,
laser Doppler flowmetry) were made non-invasively. Plasma renin activity
(PRA) and noradrenaline (NGRAD) were measured before and at 30 min in-
tervals after captopril (50 mg, oral).
Basal supine BP was higher in AF compared to normals (p < 0.05). After
captopril, mean BP fell in AF (117 ± 6 to 103 ± 5 mmHg, p < 0.05). but not in
normals (99 ± 4 to 97 ± 5 mmHg, ns). HR was unchanged after captopril in
both groups. The depressor response in AF was accompanied by a fall in SO
